CEE321A
Total Payments
$17,766
Transactions
3
Doctors
2
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $17,766 | 3 | 2 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $17,766 | 3 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A FIRST-IN-HUMAN STUDY TO DETERMINE SAFETY, TOLERABILITY AND SYSTEMIC EXPOSURE OF TOPICALLY APPLIED CEE321 CREAM IN ADULT SUBJECTS | Novartis Pharmaceuticals Corporation | $17,766 | 2 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $17,766
- Total Doctors 2
- Transactions 3
About CEE321A
CEE321A is a drug associated with $17,766 in payments to 2 healthcare providers, recorded across 3 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2020 to 2020. In 2020, $17,766 was paid across 3 transactions to 2 doctors.
The most common payment nature for CEE321A is "Unspecified" ($17,766, 100.0% of total).
CEE321A is associated with 1 research study, including "A FIRST-IN-HUMAN STUDY TO DETERMINE SAFETY, TOLERABILITY AND SYSTEMIC EXPOSURE OF TOPICALLY APPLIED CEE321 CREAM IN ADULT SUBJECTS" ($17,766).